Thirty-one immunocompromised patients with severe cytomegalovirus (CMV) disease were
treated with intravenous ganciclovir. Twenty-one patients had received transplants—15
bone marrow recipients, five renal allograft recipients, and one liver transplant recipient—
while the other ten were immunocompromised due to acquired immunodeficiency syndrome
(six), hematologic malignancies (three), and systemic lupus erythematosus (one). They
presented with one or more of the following syndromes: CMV pneumonitis (19), CMV of the …